European equities traded in the US as American depositary receipts were climbing sharply late Friday morning, rising 2.45% to 1,423.12 on the S&P Europe Select ADR Index, which is up 2.3% for the week.
From continental Europe, the gainers were led by accommodations booking company trivago (TRVG) and financial services company ING Groep (ING), which advanced 8.9% and 7.5%, respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and biopharmaceutical company Grifols (GRFS), which rose 5.9% and 4.4%, respectively.
The decliners from continental Europe were led by internet advertising firm Criteo (CRTO) and telecommunications operator Telefonica (TEF), which fell 11% and 1.5%, respectively. They were followed by furniture maker Natuzzi (NTZ) and oil and gas company TotalEnergies (TTE), which were down 1.2% and 0.4%, respectively.
From the UK and Ireland, the gainers were led by biotech firms Autolus Therapeutics (AUTL) and Trinity Biotech (TRIB), which were up 3.8% and 3.5%, respectively. They were followed by cruise line operator Carnival (CUK) and biopharmaceutical company Adaptimmune Therapeutics (ADAP), which increased 3.3% and 3.2%, respectively.
The decliners from the UK and Ireland were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Biodexa Pharmaceuticals (BDRX), which dropped 2.1% and 1.4%, respectively. They were followed by tobacco company British American Tobacco (BTI) and telecommunications operator Vodafone Group (VOD), which lost 0.2% and 0.1%, respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.